Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 198

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial

Open access
Vink, Peter, Ramon Torrell, Josep Maria, Sanchez Fructuoso, Ana, Kim, Sung-Joo, Kim, Sang-il, Zaltzman, Jeff, Ortiz, Fernanda, Campistol Plana, Josep Maria, Fernandez Rodriguez, Ana Maria, Rebollo Rodrigo, Henar, Campins Marti, Magda, Perez, Rafael, González Roncero, Francisco Manuel, Kumar, Deepali, Chiang, Yang-Jen, Doucette, Karen, Pipeleers, Lissa, Agüera Morales, Maria Luisa, Rodriguez-Ferrero, Maria Luisa, Secchi, Antonio, McNeil, Shelly A, Campora, Laura, Di Paolo, Emmanuel, El Idrissi, Mohamed, López-Fauqued, Marta, Salaun, Bruno, Heineman, Thomas C, Oostvogels, Lidia·2020·Clinical Infectious Diseases

Abstract

Background: The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy. Methods: In this phase 3, randomized (1:1), observer-blind, multicenter trial, RT recipients were enrolled and received 2 doses of RZV or placebo 1–2 months (M) apart 4–18M posttransplant. Anti–glycoprotein E (gE) antibody concentrations, gE-specific CD4 T-cell frequencies, and vaccine response rates were assessed at 1M post–dose 1, and 1M and 12M post–dose 2. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days after each dose, respectively. Solicited general symptoms and unsolicited AEs were also collected 7 days before first vaccination. Serious AEs (including biopsy-proven allograft rejections) and potential immune-mediated diseases (pIMDs) were recorded up to 12M post–dose 2. Results: Two hundred sixty-four participants (RZV: 132; placebo: 132) were enrolled between March 2014 and April 2017. gE-specific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across postvaccination time points and persisted above prevaccination baseline 12M post–dose 2. Local AEs were reported more frequently by RZV than placebo recipients. Overall occurrences of renal function changes, rejections, unsolicited AEs, serious AEs, and pIMDs were similar between groups. Conclusions: RZV was immunogenic in chronically immunosuppressed RT recipients. Immunogenicity persisted through 12M postvaccination. No safety concerns arose. Clinical Trials Registration: NCT02058589.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciz177

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 198

Metadata

Authors
Vink, P., Ramon Torrell, J. M., Sanchez Fructuoso, A., Kim, S.-J., Kim, S.-I., Zaltzman, J., Ortiz, F., Campistol Plana, J. M., Fernandez Rodriguez, A. M., Rebollo Rodrigo, H., Campins Marti, M., Perez, R., González Roncero, F. M., Kumar, D., Chiang, Y.-J., Doucette, K., Pipeleers, L., Agüera Morales, M. L., Rodriguez-Ferrero, M. L., Secchi, A., McNeil, S. A., Campora, L., Di Paolo, E., El Idrissi, M., López-Fauqued, M., Salaun, B., Heineman, T. C., & Oostvogels, L.
Venue
Clinical Infectious Diseases
Published
2019-03-07
Volume
70
Issue
2
Pages
181-190
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2922062358
Cited by
198
References
1
FWCI
16.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. https://app.cochat.ai/papers/10.1093/cid/ciz177
The paper
Vink, P., Ramon Torrell, J. M., Sanchez Fructuoso, A., Kim, S.-J., Kim, S.-I., Zaltzman, J., Ortiz, F., Campistol Plana, J. M., Fernandez Rodriguez, A. M., Rebollo Rodrigo, H., Campins Marti, M., Perez, R., González Roncero, F. M., Kumar, D., Chiang, Y.-J., Doucette, K., Pipeleers, L., Agüera Morales, M. L., Rodriguez-Ferrero, M. L., . . . Oostvogels, L. (2020). Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciz177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.